Cargando…

Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer

Histologically, bladder cancer is a heterogeneous group comprising urothelial carcinoma (UC), squamous cell carcinoma, adenocarcinomas (ACs), urachal carcinomas (UrCs), and small cell neuroendocrine carcinomas (SCCs). However, all bladder cancers have been treated so far uniformly, and targeted ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wucherpfennig, Sophie, Rose, Michael, Maurer, Angela, Cassataro, Maria Angela, Seillier, Lancelot, Morsch, Ronja, Hammad, Ehab, Baldia, Philipp Heinrich, Ecke, Thorsten H., Vögeli, Thomas-Alexander, Knüchel, Ruth, Gaisa, Nadine T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8583926/ https://www.ncbi.nlm.nih.gov/pubmed/34768978 http://dx.doi.org/10.3390/ijms222111547

Ejemplares similares

SWI/SNF Alterations in Squamous Bladder Cancers
por: Achenbach, Fabian, et al.
Publicado: (2020)

Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation
por: Morsch, Ronja, et al.
Publicado: (2020)

ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response?
por: Garczyk, Stefan, et al.
Publicado: (2018)

Fibroblast growth factor receptor (FGFR) alterations in squamous differentiated bladder cancer: a putative therapeutic target for a small subgroup
por: Baldia, Philipp H., et al.
Publicado: (2016)

EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer
por: Rose, Michael, et al.
Publicado: (2020)

Epigenetic inactivation of ST6GAL1 in human bladder cancer
por: Antony, Pia, et al.
Publicado: (2014)

Comparative genomic profiling of glandular bladder tumours
por: Maurer, Angela, et al.
Publicado: (2020)

Effective Radiosensitization of Bladder Cancer Cells by Pharmacological Inhibition of DNA-PK and ATR
por: Chughtai, Ahmed Ali, et al.
Publicado: (2022)

Diagnostic and Prognostic Implications of FGFR3(high)/Ki67(high) Papillary Bladder Cancers
por: Geelvink, Mirja, et al.
Publicado: (2018)

The ECM Modulator ITIH5 Affects Cell Adhesion, Motility and Chemotherapeutic Response of Basal/Squamous-Like (BASQ) Bladder Cancer Cells
por: Rose, Michael, et al.
Publicado: (2021)

Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications
por: Barth, Isabella, et al.
Publicado: (2018)

Molecular Diagnostic and Prognostication Assays for the Subtyping of Urinary Bladder Cancer Are on the Way to Illuminating Our Vision
por: Ecke, Thorsten H., et al.
Publicado: (2022)

Molecular Characterization of Muellerian Tumors of the Urinary Tract
por: Ortiz-Brüchle, Nadina, et al.
Publicado: (2021)

Evaluating the Utility of Combined Bladder Cancer Biomarkers, the Molecular Prognostication of Tumor Subtypes, or What Else Is Needed to Illuminate Our Vision?
por: Ecke, Thorsten H., et al.
Publicado: (2020)

Promoter methylation of DNA damage repair (DDR) genes in human tumor entities: RBBP8/CtIP is almost exclusively methylated in bladder cancer
por: Mijnes, Jolein, et al.
Publicado: (2018)

Heterogenous NECTIN4 expression in urothelial high-risk non-muscle-invasive bladder cancer
por: Garczyk, Stefan, et al.
Publicado: (2022)

The prognostic value of histological subtype in patients with metastatic bladder cancer
por: Chen, Cheng, et al.
Publicado: (2017)

Pure high-grade papillary urothelial bladder cancer: a luminal-like subgroup with potential for targeted therapy
por: Schnitzler, Tician, et al.
Publicado: (2020)

Editorial: Identifying novel biomarkers in bladder cancer
por: Ecke, Thorsten H., et al.
Publicado: (2023)

ITIH5 and ECRG4 DNA Methylation Biomarker Test (EI-BLA) for Urine-Based Non-Invasive Detection of Bladder Cancer
por: Rose, Michael, et al.
Publicado: (2020)

Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer
por: Jung, Max, et al.
Publicado: (2023)

Establishment and Characterization of an Empirical Biomarker SS/PV-ROC Plot Using Results of the UBC(®) Rapid Test in Bladder Cancer
por: Oehr, Peter, et al.
Publicado: (2020)

Illumination of a Vision 2020—Urinary Based Biomarkers for Bladder Cancer on the Way to Clinical Decisions—Dream or Nightmare?
por: Ecke, Thorsten H., et al.
Publicado: (2020)

Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer
por: Garczyk, Stefan, et al.
Publicado: (2021)

Illumination of a Vision—How Arthur Rimbaud Will Give Us Motivation to Find New Input into Bladder Cancer Biomarker Research
por: Ecke, Thorsten H., et al.
Publicado: (2017)

Diagnostic and Prognostic Potential of MicroRNA Maturation Regulators Drosha, AGO1 and AGO2 in Urothelial Carcinomas of the Bladder
por: Rabien, Anja, et al.
Publicado: (2018)

Presentation of a Self-peptide in Two Distinct Conformations by a Disease-associated HLA-B27 Subtype
por: Wucherpfennig, Kai W.
Publicado: (2004)

Genetic polymorphisms in interleukin-1β (rs1143634) and interleukin-8 (rs4073) are associated with survival after resection of intrahepatic cholangiocarcinoma
por: Lurje, Isabella, et al.
Publicado: (2023)

Prediction of Response to Cisplatin-Based Neoadjuvant Chemotherapy of Muscle-Invasive Bladder Cancer Patients by Molecular Subtyping including KRT and FGFR Target Gene Assessment
por: Ecke, Thorsten H., et al.
Publicado: (2022)

A Methylation-Based Reclassification of Bladder Cancer Based on Immune Cell Genes
por: Luo, Qizhan, et al.
Publicado: (2020)

Evaluation of PD-L1 and other immune markers in bladder urothelial carcinoma stratified by histologic variants and molecular subtypes
por: Li, Huili, et al.
Publicado: (2020)

Lung Cancer Prevalence in Iran by Histologic Subtypes
por: Vardanjani, Hossein Molavi, et al.
Publicado: (2017)

Controversies and challenges in the histologic subtyping of lung adenocarcinoma
por: Butnor, Kelly J.
Publicado: (2020)

FIGO staging in ovarian carcinoma and histological subtypes
por: Kehoe, Sean
Publicado: (2020)

Histologic subtyping of ampullary carcinoma for targeted therapy
por: Hong, Seung-Mo
Publicado: (2021)

Epidemiology of Unconventional Histological Subtypes of Urethral Cancer
por: Wenzel, Mike, et al.
Publicado: (2023)

Identification and Validation of Potential New Biomarkers for Prostate Cancer Diagnosis and Prognosis Using 2D-DIGE and MS
por: Geisler, Cordelia, et al.
Publicado: (2015)

Adenocarcinoma with mixed subtypes is a rare but aggressive histologic subtype in colorectal cancer
por: Sheng, Hui, et al.
Publicado: (2019)

Prognostic Value of Histologic Subtype and Treatment Modality for T1a Kidney Cancers()
por: Siev, Michael, et al.
Publicado: (2020)

Sitzungsbericht der Arbeitsgemeinschaft Uropathologie der Deutschen Gesellschaft für Pathologie 2021
por: Reis, Henning, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9b6m05fe18b5rf0fcipfg5hvg8